Talphera (NASDAQ:TLPH) and Supreme Cannabis (OTCMKTS:SPRWF) Critical Survey

Supreme Cannabis (OTCMKTS:SPRWF) and Talphera (NASDAQ:TLPH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Profitability

This table compares Supreme Cannabis and Talphera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Supreme Cannabis	N/A	N/A	N/A
Talphera	N/A	-87.28%	-51.36%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Supreme Cannabis and Talphera, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supreme Cannabis	0	0	0	0	0.00
Talphera	1	1	2	0	2.25

Talphera has a consensus price target of $3.00, suggesting a potential upside of 152.10%. Given Talphera’s stronger consensus rating and higher probable upside, analysts clearly believe Talphera is more favorable than Supreme Cannabis.

Institutional and Insider Ownership

37.7% of Talphera shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Supreme Cannabis and Talphera”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supreme Cannabis	N/A	N/A	N/A	N/A	N/A
Talphera	$30,000.00	2,058.70	-$14.29 million	($0.27)	-4.41

Supreme Cannabis has higher earnings, but lower revenue than Talphera.

Summary

Talphera beats Supreme Cannabis on 6 of the 8 factors compared between the two stocks.

About Supreme Cannabis

The Supreme Cannabis Company, Inc. engages in the production of medical cannabis products in Canada. The company was formerly known as Supreme Pharmaceuticals Inc. and changed its name to The Supreme Cannabis Company, Inc. in December 2017. The Supreme Cannabis Company, Inc. was incorporated in 1979 and is headquartered in Toronto, Canada.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.